Trialbee Honey™ Adds New Features
Latest enhancements will optimize Omnichannel capabilities for ROI reporting.
Trialbee has enhanced its Omnichannel recruitment strategy by adding features for transparency into performance across all channels, sources, and recruitment partners.
Available in the Trialbee Honey™ platform, these vendor-agnostic insights provide real-time ROI data, With Honey Omnichannel, customers can:
- Understand the current status, progress, and trajectory of their enrollment milestones.
- Objectively evaluate partner performance including third-party recruitment providers, CROs, patient advocacy groups, and more.
- Dive deep into the relative value of specific social channels (e.g., Facebook, Instagram, TikTok), digital mediums (email, social, programmatic), and individual campaigns by each referrer in their recruitment ecosystem.
By aggregating and analyzing all referrer channels into a single funnel with visual dashboards and insightful analytics, Trialbee Honey™ enables enrollment outcomes through stronger candidate sourcing.
Reference
Trialbee Honey™ Adds New Features to Optimize Omnichannel Capabilities for ROI Reporting Across All Patient Recruitment Sources and Vendors. (2023, May 17). Cision PRWeb.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
